Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Katerina G. Tsegka, Georgios L. Voulgaris, Margarita Kyriakidou, Anastasios Kapaskelis & Matthew E. Falagas. (2022) Intravenous fosfomycin for the treatment of patients with bone and joint infections: a review. Expert Review of Anti-infective Therapy 20:1, pages 33-43.
Read now
Read now
I Byren, EJG Peters, C Hoey, A Berendt & BA Lipsky. (2009) Pharmacotherapy of diabetic foot osteomyelitis. Expert Opinion on Pharmacotherapy 10:18, pages 3033-3047.
Read now
Read now
Philippa C Matthews, Anthony R Berendt & Benjamin A Lipsky. (2007) Clinical management of diabetic foot infection: diagnostics, therapeutics and the future. Expert Review of Anti-infective Therapy 5:1, pages 117-127.
Read now
Read now
Articles from other publishers (18)
Laura Soldevila-Boixader, Oscar Murillo, Felix W. A. Waibel, Tanja Huber, Madlaina Schöni, Rahim Lalji & Ilker Uçkay. (2023) The Epidemiology of Antibiotic-Related Adverse Events in the Treatment of Diabetic Foot Infections: A Narrative Review of the Literature. Antibiotics 12:4, pages 774.
Crossref
Crossref
Maggie Wong, Davie Wong & Sangita Malhotra. (2021)
Intravenous fosfomycin as salvage therapy for osteomyelitis caused by multidrug-resistant
Pseudomonas aeruginosa
. American Journal of Health-System Pharmacy 78:24, pages 2209-2215.
Crossref
Crossref
T. Dimski, T. Brandenburger, M. Janczyk, T. Slowinski, C. MacKenzie & D. Kindgen-Milles. (2021) Elimination of fosfomycin during dialysis with the Genius system in septic patients. Scientific Reports 11:1.
Crossref
Crossref
George G. Zhanel, Michael A. Zhanel & James A. Karlowsky. (2018) Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada. Canadian Journal of Infectious Diseases and Medical Microbiology 2018, pages 1-13.
Crossref
Crossref
A. Pourbaix & F. Guérin. (2016) Fosfomycine, place et intérêt dans un contexte de multirésistance. Journal des Anti-infectieux 18:3, pages 85-97.
Crossref
Crossref
Dmitri Iarikov, Ronald Wassel, John Farley & Sumathi Nambiar. (2015) Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database. Infectious Diseases and Therapy 4:4, pages 433-458.
Crossref
Crossref
Wei-chen Chang, Mishtu Dey, Pinghua Liu, Steven O. Mansoorabadi, Sung-Ju Moon, Zongbao K. Zhao, Catherine L. Drennan & Hung-wen Liu. (2013) Mechanistic studies of an unprecedented enzyme-catalysed 1,2-phosphono-migration reaction. Nature 496:7443, pages 114-118.
Crossref
Crossref
J.I. Blanes, A. Clará, F. Lozano, D. Alcalá, E. Doiz, R. Merino, J. González del Castillo, J. Barberán, R. Zaragoza & J.E. García Sánchez. (2012) Documento de consenso sobre el tratamiento de las infecciones en el pie del diabético. Angiología 64:1, pages 31-59.
Crossref
Crossref
Christian Eckmann & Matthew Dryden. (2010) Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin. European Journal of Medical Research 15:12.
Crossref
Crossref
L. Gutierrez, L. Ocampo, C. Rosario & H. Sumano. (2010) Pharmacokinetics of disodium fosfomycin in broilers and dose strategies to comply with its pharmacodynamics versus Escherichia coli. Poultry Science 89:10, pages 2106-2115.
Crossref
Crossref
M. Popovic, D. Steinort, S. Pillai & C. Joukhadar. (2009) Fosfomycin: an old, new friend?. European Journal of Clinical Microbiology & Infectious Diseases 29:2, pages 127-142.
Crossref
Crossref
Nikos Roussos, Drosos E. Karageorgopoulos, George Samonis & Matthew E. Falagas. (2009) Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. International Journal of Antimicrobial Agents 34:6, pages 506-515.
Crossref
Crossref
Sandra Bliss Nelson. (2009) Management of diabetic foot infections in an era of increasing microbial resistance. Current Infectious Disease Reports 11:5, pages 375-382.
Crossref
Crossref
D. H. ZOZAYA, O. L. GUTIRREZ, C. L. OCAMPO & L. H. SUMANO. (2008) Pharmacokinetics of a single bolus intravenous, intramuscular and subcutaneous dose of disodium fosfomycin in horses. Journal of Veterinary Pharmacology and Therapeutics 31:4, pages 321-327.
Crossref
Crossref
Jeffrey W. Munos, Sung-Ju Moon, Steven O. Mansoorabadi, Weichen Chang, Lin Hong, Feng Yan, Aimin Liu & Hung-wen Liu. (2008)
Purification and Characterization of the Epoxidase Catalyzing the Formation of Fosfomycin from
Pseudomonas syringae
. Biochemistry 47:33, pages 8726-8735.
Crossref
Crossref
A. Dinh, J.-P. Bru, I. Dresco, C. Janus & L. Bernard. (2008) Prescription de la fosfomycine en situation critique. Médecine et Maladies Infectieuses 38:7, pages 383-386.
Crossref
Crossref
Matthew E. Falagas, Konstantina P. Giannopoulou, George N. Kokolakis & Petros I. Rafailidis. (2008) Fosfomycin: Use Beyond Urinary Tract and Gastrointestinal Infections. Clinical Infectious Diseases 46:7, pages 1069-1077.
Crossref
Crossref
Feng Yan, Jeffrey W. Munos, Pinghua Liu & Hung-wen Liu. (2006) Biosynthesis of Fosfomycin, Re-Examination and Re-Confirmation of a Unique Fe(II)- and NAD(P)H-Dependent Epoxidation Reaction. Biochemistry 45:38, pages 11473-11481.
Crossref
Crossref